TransMedics still looks undervalued even at $94 after a strong Q2 earnings report, which puts it back on the buy list. The company has quietly been crushing it. x.com 

Better underwriting at Root, AI data demand at Innodata, defense breadth at Applied Aerospace & Defense, scaled voice AI at SoundHound, more organ access via TransMedics, profitable insurance at Lemonade, autonomous defense at Ondas and successful medicines at AbCellera could drive outsized growth. These eight smaller companies have a realistic path to 5x+ over 5-10 years if they execute on those opportunities. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

TransMedics' best trade is likely over: in biotech, by the time competition starts being discussed, most of the gain has been made. Another investor notes its technology is great but very expensive, with many working to replace it. x.com 

TransMedics' long-term story stands despite a roughly 60% stock drop, because its organ transplant model is hard to replicate. It sells the machines and also handles retrieval and transport with its own aviation fleet and clinical teams. Margins are compressed by deliberate heavy investment, alongside regulatory issues and a lingering short report. About three-quarters of the TAM remains in the US, Europe is opening through Italy and PAD Aviation, and kidney transplants could double the TAM. … Show more

TransMedics, Hims & Hers, Harrow, PROCEPT BioRobotics, ClearPoint Neuro, Alphatec and Compass Pathways can double in 2–3 years and triple in 3–5 because these small- and mid-cap healthcare names trade at only 2–3x next-12-month revenue. Software and cloud stocks people are chasing at 20–30x make such returns hard. Alphatec looks attractive after its earnings selloff, while Compass is very speculative and should not be chased. x.com 

TransMedics' investment case is broken because operating margins are tracking near 11% instead of the expected path above 21%, and management is signaling further near-term pressure as investment continues. That gap is too large to stay invested. x.com 

Fintech is investing while biotech is gambling: roughly 90% of biotechs fail versus 10% of fintechs. Most fintechs are growing 25-30% or more yet trade at record-low valuations, while biotech is already up 90% and in a bubble driven by buyout mania. x.com 

TransMedics is due for a re-rating as it becomes a fully integrated logistics network for organ transplants, not just a device maker. Its 22 aircraft flew nearly 9,000 missions last year, supporting about 26% of US transplants. It targets 10,000 US cases by 2028 and 30,000 globally by 2032, helped by a kidney platform, and projects revenue rising from $605 million to $2.5-3 billion in four to five years. It is high risk, high reward, with a possible 100%+ rebound in two to three months. x.com  … Show more

TransMedics now looks weak, and weak names are not worth touching regardless of how cheap they look. The market is selling on falling operating margins; rising costs come from R&D and clinical trials, which is healthy, but there is more to it than margins. TransMedics is not passing fuel costs fully to customers, covering only part with a flat fee, and it is now offering cold-storage transplants, shifting from running both trial arms itself to offering the service. x.com  x.com  x.com  x.com  x.com 

Q1 medical device fears are overblown, a positive for small- and mid-cap device makers such as AngioDynamics. Johnson & Johnson's medical device trends look like normal seasonality. Boston Scientific, by contrast, now looks like a poor company. x.com